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Hospitalized avascular necrosis after renal transplantation in true scope of this condition is controversial. Avascular
the United States. necrosis results from the death of living elements in bone
Background. The national incidence of and risk factors for and is not a specific disease but rather the end result ofhospitalized avascular necrosis (AVN) in renal transplant re-
many conditions [3]. This complication has been mostcipients has not been reported.
intensively studied in patients with systemic lupus ery-Methods. This historical cohort study consisted of 42,096
renal transplant recipients enrolled in the United States Renal thematosus, where the prevalence of AVN has been re-
Data System (USRDS) between 1 July 1994 and 30 June 1998. ported as high as 12% (lupus anticoagulant also was as-
The data source was USRDS files through May 2000. Associa-
sociated independently with AVN in this study) [4]. Intions with hospitalizations for a primary diagnosis of AVN (ICD-9
addition to corticosteroid therapy, other risk factors forcodes 733.4x) within three years after renal transplant were as-
sessed in an intention-to-treat design by Cox regression analysis. AVN include sickle cell anemia, fatty emboli, and alco-
Results. Recipients had a cumulative incidence of 7.1 epi- holism [5, 6]. The role of other risk factors, including
sodes/1000 person-years from 1994 to 1998. The two-year inci- race, weight, duration of dialysis prior to transplant, anddence of AVN did not change significantly over time. Eighty-
cause of end-stage renal disease (ESRD) are contro-nine percent of the cases of AVN were due to AVN of the hip
versial. Further, the role of definitive surgical therapy(733.42) and 60.2% of patients with AVN underwent total hip
arthroplasty (THA); these percentages did not change signifi- (usually total hip arthroplasty, or THA) in patients hos-
cantly over time. In the Cox regression analysis, an earlier year pitalized for AVN has not been reported in a national
of transplant, African American race [adjusted hazard ratio population. Therefore, we analyzed national data from(AHR), 1.65, 95% confidence interval (CI) 1.33 to 2.03], allo-
the United States Renal Data System (USRDS) report.graft rejection (AHR 1.67, 95% CI 1.35 to 2.07), peritoneal di-
Our objectives were to determine the rate of and riskalysis (vs. hemodialysis; AHR 1.44, 95% CI 1.15 to 1.81), and
diabetes (AHR 0.41, 95% CI 0.27 to 0.64) were the only factors factors for hospitalizations for a primary diagnosis of
independently associated with hospitalizations for AVN. AVN in renal transplant recipients, as well as the utiliza-
Conclusions. The incidence of AVN did not decline signifi-
tion of definitive surgery in this complication.cantly over time in the renal transplant population. Patients
with allograft rejection, African American race, peritoneal dial-
ysis and earlier date of transplant were at the highest risk of
METHODSAVN, while diabetic recipients were at a decreased risk.
Patient population
This study examined data from the USRDS, using stan-
Avascular necrosis (AVN), especially AVN of the hip, dard analysis files (SAFs) as of May 2000. The USRDS,
has been reported to be an uncommon but serious com- indirectly mandated by federal law, incorporates base-
plication after renal transplantation [1, 2]. However, the line and follow-up demographic and clinical data on all
rates of and risk factors for AVN have not been analyzed patients receiving ESRD therapy in the United States.
for a national transplant population, and therefore the ESRD therapy includes hemodialysis, peritoneal dialysis,
and renal transplantation. Because patient entry into
the USRDS is linked to Medicare reimbursement, andKey words: osteonecrosis, hip, total hip arthroplasty, kidney rejection,
year of transplant, complications, USRDS, bone pain post-transplant. ESRD services are expensive, very few transplant pa-
tients are not represented in the database. The variables
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base,” Section E, “Contents of all the SAF’s,” http:// ESRD (diabetes, systemic lupus erythematosus). Epi-
sodes of rejection were not restricted to those occurringwww.usrds.org) and published in the USRDS. The demo-
graphics of the renal transplant population have been pre- in the first year, in contrast to studies of allograft func-
tion, since there is no evidence that late (vs. early) rejec-viously described (2001 USRDS report). SAF.TXUNOS
was used as the primary dataset, and merged with vari- tion has a different impact on AVN. The total cumulative
dose of prednisone was not available in the USRDS.ables from SAF.HOSP for hospitalization data, and
SAF.PATIENTS for dates and causes of death as well UNOS tracks the numbers of days of prednisone admin-
istered prior to initial hospital discharge; however, valuesas causes of renal disease, as previously reported [7–9].
Patient characteristics and treatment factors were those were missing for 90% of patients in both databases and
could not be used as a covariate in the above analyses.at the date of transplant. Recipients of organs other than
kidneys were excluded. The use of maintenance immunosuppressive medication
at the time of discharge after transplantation also was
Outcome definition analyzed as a preexisting covariate. Information on use
of medications (other than immunosuppressive medica-This historical cohort study was conducted to examine
the incidence, risk factors and associated patient survival tions), alcohol, tobacco, or radiologic procedures was
not available. Dialysis modality was obtained from thefor hospitalized cases of AVN [based on International Clas-
sification of Diseases-9th Modification Diagnosis Codes file SAF.RXHIST60. The initial dialysis modality a pa-
tient used for at least 60 days after presentation to ESRD(ICD9) at hospital discharge for AVN, 733.4x, excluding
avascular necrosis due to malignancy] as a primary dis- was utilized in an intention-to-treat fashion.
charge diagnosis in renal transplant recipients. The first
Survival timeshospitalization for AVN after the first renal transplant
for a given individual occurring on or after July 1, 1994 To determine the time to AVN value, survival time
and before July 1, 1998, with follow-up time truncated at was defined as the time from first renal transplant until
three years was counted in the analysis. Hospitalizations hospitalization for AVN, with patients censored at death,
were chosen because they were more accessible in the loss to follow-up, or end of the study. The patient survival
database and less subject to interpretation than outpa- probabilities were estimated by using the Kaplan Meier
tient cases of AVN, especially since the USRDS database method.
has no information on confirmatory studies. Hospitaliza-
Statistical analysistion data for transplant recipients may be unreliable after
the patient has survived 3 years post-transplant, when All analyses were performed using SPSS 9.0 TM
hospitalization reporting to Medicare for patients 65 (SPSS, Inc., Chicago, IL, USA). Files were merged and
years or younger is no longer required. However, Medi- converted to SPSS files using DBMS/Copy (Conceptual
care reporting starts immediately after transplant, re- Software, Houston, TX, USA). Univariate analysis was
gardless of the preceding dialysis status. All hospitaliza- performed with Chi-square testing for categorical vari-
tions with a primary discharge diagnosis for AVN were ables and Student’s two-sided t test for continuous vari-
extracted from SAF.HOSP, merged with the transplant ables. Variables with P  0.10 in univariate analysis for
file using unique identifiers, and hospitalizations outside a relationship with the development of hospitalization
the range of the study period were excluded. Hospitaliza- for AVN were entered into multivariate analysis as co-
tions for AVN occurring at any time after renal trans- variates. Life table analyses were used to calculate two-
plant, including after graft failure (censored for patient year incidences of AVN by year of transplantation.
death), were counted in the analysis. Kaplan-Meier analysis was used to construct survival plots
of time to hospitalized AVN after renal transplantation.
Variables used in the analysis Stepwise Cox regression (likelihood ratio method) was
The independent associations between patient factors used to model factors associated with time to hospital-
and hospitalizations for AVN were examined using mul- ized AVN, controlling for covariates listed above.
tivariate analysis with stepwise analysis including recipi-
ent and donor age, recipient race, gender, weight, pre-
RESULTStransplant dialysis (yes/no), duration of dialysis prior to
There were 42,096 solitary renal transplant recipientstransplantation, total follow-up time, repeat transplant,
in the United States Renal Data System transplanteddonor cytomegalovirus serology, dialysis in the first week
from July 1, 1994 to June 30, 1998. Of these, 563 recipi-after transplant (delayed graft function, yes/no), rejec-
ents were hospitalized with a primary discharge diagnosistion (either treatment or diagnosis) occurring at any time
of AVN, with 645 total hospitalizations. The incidencein the study period, induction antibody therapy, main-
of hospitalized AVN in renal transplant recipients wastenance immunosuppressive medications at time of dis-
charge after transplant surgery, graft loss, and cause of 7.1 episodes/1000 patient-years. The most recent hospi-
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Fig. 1. Two-year incidence of hospitalized avascular necrosis (AVN)
after renal transplantation (per 100,000 patient-years), by year of renal
transplantation ( ). The right column () represents the proportion
of patients hospitalized for AVN who underwent total hip replacement
Fig. 2. Time to hospitalization for AVN, U.S. renal transplant recipi-(THR, also within two years post-transplant). Neither the incidence of
ents from July 1, 1994 to 1998. N  42,096 patients, with a follow-upAVN nor the proportion of patients with AVN who underwent THR
period truncated at three years post-transplant. The proportion of pa-changed significantly over time.
tients who experienced AVN in the first post-transplant year was 0.26%,
compared with 0.83% in the second post-transplant year and 0.84% in
the third post-transplant year. As shown, in contrast to prior studies,
the risk of AVN was actually lowest in the first transplant year and
talization date was December 28, 1999. The most recent increased at a similar rate the remaining two years. This may reflect
the preferred timing of total hip replacement, which is the definitivedate of death was April 2000. Twenty-seven patients had
therapy for AVN.hospitalized AVN after graft loss. Of recipients hospital-
ized for AVN, 89% had AVN of the hip, 5.0% had AVN
site unspecified, 2.7% had AVN of the humerus, 2.1%
had AVN of the femoral condyle, and 0.9% had AVN tients who underwent THA were excluded from analysis,
of the talus. Of the recipients hospitalized for AVN, all of the associations in this paragraph, including that
60.2% (339) underwent total hip arthroplasty (THA), with diabetes, persisted.
and another 6.9% underwent some type of hip arthro- In multivariate analysis with hospitalization for AVN
plasty. Of the patients hospitalized for AVN who did after transplantation as the outcome variable, significant
not undergo THA, 19.5% underwent bone excision of associations were found with earlier year of transplant,
the femur, and 14.1% underwent bone grafting to the African American race, rejection, peritoneal dialysis, and
femur. The two-year incidence of AVN, along with the ESRD due to diabetes (Table 2). There were no sig-
proportion of patients hospitalized for AVN who under- nificant interactions between covariates, specifically no
went THA (also within 2 years of transplant), is shown interactions between maintenance or induction medica-
in Figure 1. There was no significant change in the inci- tions. Body mass index (BMI) was not significant either
dence of AVN or the proportion of patients with AVN as a continuous or categorical variable.
who underwent THA over time. The time to hospitaliza-
tion for AVN is shown in Figure 2, which depicts a low
DISCUSSIONrate of hospitalized AVN the first year after transplan-
tation, and a steady increase afterward, even after two The present study of a national renal transplant popu-
lation confirms the widely held impression that hospital-years.
Continuous variables in patients hospitalized for AVN ized AVN is becoming less frequent in renal transplant
recipients [10–12]. All patients in the study had the po-vs. all other renal transplant recipients is shown in Ta-
ble 1. Only body mass index and duration of follow-up tential for at least 20 months of follow-up. Although we
were unable to capture cases of AVN managed on andiffered significantly by AVN status.
In univariate analysis (Table 2), recipient African outpatient basis, the consistent ratio of patients hospital-
ized for AVN who underwent THA (Fig. 1) indicatesAmerican race, recipient weight, diabetes, hypertension
and glomerulonephritis as causes of ESRD, peritoneal that the declining incidence of hospitalized AVN was
not merely due to differences in hospital utilization, sincedialysis (vs. hemodialysis) and donor type were signifi-
cantly different between recipients hospitalized for AVN the primary reason for hospitalization of patients with
AVN appeared to be for THA. Perhaps the most strikingversus all other recipients. Recipients with hospitalized
AVN were older than other recipients. The number of finding of the study is that, as a hospitalized diagnosis
after renal transplantation, avascular necrosis (7.1/1000days of prednisone use prior to discharge was analyzed
as a categorical variable by quartiles, but still had no person-years) was nearly as common as all causes of hospi-
talized fractures combined (7.2/1000 person-years) usingsignificant association with hospitalized AVN. When pa-
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Table 1. Continuous variables associated with hospitalized avascular necrosis in renal transplant recipients hospitalized for
avascular necrosis (AVN) versus all other renal transplant recipients, July 1, 1994–June 30, 1998a
Renal transplant recipients
Missing,
Factor with AVN without AVN N (%)
Recipient mean age years 43.812.8 43.414.9 3 (0.1)
Donor mean age years 35.616.3 35.915.9 920 (2.2)
HLA mismatches (0–4) 2.31.2 2.31.3 0
HLA-DR mismatches (0–2) 1.10.7 1.10.7 0
Body mass index kg/m2 26.014.9b 25.25.3 15,005 (35.6)
Follow-up time years 2.51.1b 1.91.1 2468 (5.9)
Year of transplant 1995.61.0 1995.91.2b 0
Data are given as the mean  one standard deviation.
a Follow-up time truncated at three years post-transplant
b P  0.05 by the student t test vs. renal transplant recipients without AVN
Table 2. Categorical variables of renal transplant recipients hospitalized for avascular necrosis (AVN) versus all other renal transplant
recipients, July 1, 1994–June 30, 1998a,b
Unadjusted HR Adjusted HR
Renal transplant Missing,
Factor recipients N (%) for AVN
N 42,096
Male recipient 23,827 (60.1) 0
African American 9142 (23.1) 640 (1.5) 1.52 (1.27–1.82) 1.65 (1.33–2.03)
Graft loss 2815 (6.5%) 0
Cadaveric donor 27,369 (69.1) 0
History of peritoneal dialysis
(vs. hemodialysis) 8260 (19.6) 7855 (18.7) 1.34 (1.11–1.63) 1.44 (1.15–1.81)
Recipient HCV positive 2198 (5.6) 5743 (13.6)
Donor CMV positive 23,552 (57.1) 1620 (3.8)
More recent year of transplant
(compared with 1994) 0
Dialysis in the first week
post-transplant 7682 (18.5) 2382 (5.7)
Rejection 8335 (19.8) 0 1.58 (1.28–1.95) 1.67 (1.35–2.07)
Cause of ESRD (vs. all others)
Diabetes 7862 (19.7) 5178 (12.3) 0.31 (0.21–0.47) 0.41 (0.27–0.64)
Systemic lupus erythematosus 1329 (3.2) 5178 (12.3)
Maintenance medications
(each medication vs. all others)
Cyclosporine 31,448 (74.7) 3372 (8) 1.79 (1.43–2.24)
Tacrolimus 4623 (11.9) 3372 (8) 0.49 (0.35–0.70)
Mycophenolate 18,608 (47.9) 3221 (7.6)
Azathioprine 16,308 (41.9) 3157 (7.5) 1.22 (1.03–1.45)
Prednisone 34,451 (90.1) 3880 (9.2)
Induction antibody therapy 11,905 (28.3) 2277 (5.4)
Data are given as the number (% of total) mean  one standard deviation. Abbreviations are: HR, hazard ratios; AVN, hospitalization for avascular necrosis;
defined as ICD9 code 733.4x; HCV, hepatitis C virus; CMV, cytomegalovirus; ESRD  end-stage renal disease.
a Follow-up time truncated at three years post transplant
b P  0.01 vs. all other recipients by Chi square test vs. recipients without AVN
the same patient population [13]. Reports on the natural providers in attempting to avoid THA, a major elective
surgery, in the first transplant year (when steroid dosinghistory of hospitalized AVN after renal transplantation
are few, but those available indicate that conservative is usually higher and may impair wound healing), rather
than the time at which patients develop symptoms. Wetherapy suffices for 40% of cases of AVN of the hip [14].
This is similar to the findings of the present study. In were unable to assess cases in which intraosseous ple-
thysmography and venography for core decompressioncontrast to frequent reports that 80% of patients with AVN
become symptomatic within two years post transplant [16] were performed, as these were not coded by ICD9
procedure codes, and may be performed as outpatient[15], Figure 2 indicates that the risk of hospitalized AVN
from two to three years after transplant is essentially the therapy. However, bone excision and bone grafting could
be assessed. Although these procedures also presumablysame as the risk from one to two years. The apparent
low risk for hospitalized AVN within one year after would require hospitalization, they were much less com-
mon as hospitalized procedures for AVN than THA.transplant may reflect caution on the part of transplant
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Many studies relate the development of hospitalized of graft loss [23]. African American race has been cited
as a risk factor for AVN in the transplanted [11] andAVN to the use of corticosteroids. Because of limitations
of the USRDS database, there was no information on general populations, although the strong association of
African American race with SLE probably confoundsthe cumulative steroid dosages patients received. We
were thus unable to construct a “dose-response” curve this observation. AVN has been infrequently reported
in patients with sickle cell trait [24], while sickle cellto determine a threshold cumulative dose of prednisone
and the development of hospitalized AVN, which would disease is a known risk factor for AVN [25]. Although
it is possible that the sickle cell trait and corticosteroidhave been clinically useful. However, no previous study
of AVN—whether in renal transplantation or in patients treatment might be synergistic for the risk of AVN, stud-
ies of patients with SLE have not identified race as anwith systemic lupus erythematosus—has clearly shown
a “threshold” cumulative dose associated with AVN. independent risk factor for AVN when the total dose of
corticosteroids was taken into account [26].Although many studies have identified corticosteroids as
a risk factor for AVN, most were small and retrospective, Recent reports indicate that 3-hydroxy-3-methlyglu-
taryl coenzyme A (HMG-CoA) reductase inhibitors (sta-without controls, and were conducted in patients with
systemic lupus erythematosus (SLE) [17]. Comparison tins) may reduce the risk of osteonecrosis in patients
receiving corticosteroid therapy [27]. Statins also increasebetween studies of AVN in patients with SLE also may
be confounded by pre-existing bone disease in most bone mineral density and reduce the risk of osteoporotic
fractures [28], although the relevance of this mechanismtransplant recipients. Whether hyperparathyroid or ady-
namic bone disease contributes to the risk of AVN has to AVN is controversial. Although we were unable to
determine use of statins in our population, statin use isnot been confirmed. The largest previous study of AVN
in renal transplantation was by Fryer et al, who studied increasing in the ESRD population [29]. The role of hyper-
lipidemia in AVN also has been suggested by studies in748 adult kidney transplant recipients with at least one
year of follow-up [18]. In that cohort, 5.5% of recipients patients with Gaucher disease [30], and the connection
between hyperlipidemia and AVN after renal trans-developed AVN (mean follow-up and incidence not
given). However, while the duration of steroid use was plantation needs to be explored in future studies.
Diabetes has not been studied in analysis of risk forindependently associated with all bone related complica-
tions, it was not independently associated with the risk AVN in previous studies. Since 63% of recipients hospi-
talized for AVN underwent total hip arthroplasty, hospi-of AVN. Furthermore, the overall rate of hospitalized
AVN in patients taking corticosteroids is still low. The talization was most commonly employed for definitive
procedures in this condition. Diabetes is a known riskHopkins Lupus Cohort Trial found that each two-month
exposure to high-dose (1 mg/kg/day) prednisone, but factor for infection [31, 32] and cardiovascular disease
[33, 34] after renal transplantation. Therefore, diabeticnot the total cumulative prednisone dose or individual
pulse doses of prednisone, increased the risk of AVN in patients may succumb from other causes and not live long
enough to develop AVN or other indications for THAlupus patients [19]. In a case control study of 42 patients
with systemic lupus erythematosus, 17 of whom devel- after renal transplantation, or diabetic candidates may be
considered poor candidates for THA. Another possibleoped AVN versus 25 who did not, the patients who
developed AVN had received higher doses of corticoste- explanation is that diabetic patients may have more rapid
tapering of corticosteroids doses and thus less cumulativeroids in the first one, three and six months of therapy
[20]. Neither the duration of therapy nor the total dose steroid exposure after transplantation [35]. In contrast
to diabetes as a cause of renal disease, post-transplant dia-of corticosteroids differed between groups.
The significance of rejection, which has been a risk betes has been associated with a high risk of AVN [36].
However, we were unable to assess for the new develop-factor for post-transplant AVN in prior studies [21], may
represent recipients who received substantially higher ment of diabetes after transplantation in the USRDS
database. Diabetes also has an association with adynamiccumulative doses of corticosteroids, since although recip-
ients are usually tapered to approximately 10 mg per bone disease prior to transplantation [37]. The present
study results showed an association between AVN andday of prednisone within the first few months of trans-
plant, those who experience rejection are often “recy- a prior history of peritoneal dialysis, which also has an
association with adynamic bone disease [38]. Adynamiccled” (restarted on higher oral doses of corticosteroids
and continued for a longer time) in addition to pulse bone disease also has a strong negative association with
African American race [39]. The negative association be-corticosteroid therapy [22]. The significance of African
American race may represent the inability of the present tween diabetes and Caucasian race with AVN in the pres-
ent analysis is intriguing but cannot be fully explained bystudy to account for cumulative doses of corticosteroids,
since African Americans usually receive higher cumula- the database.
There are several limitations to this retrospective study.tive doses of immunosuppression due to their poorer
HLA matching and sensitization leading to higher risk Findings are associative, not causative, and risk cannot
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